EUVIMEDEUVIMED entdecken
Crossref

Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer

Toru Sakatani iD, Takayuki Sumiyoshi iD, Yuki Kita, Hideaki Takada, Kenji Nakamura iD, Akihiro Hamada, Kaoru Murakami, Takeshi Sano iD, Takayuki Goto, Atsuro Sawada iD, Shusuke Akamatsu iD, Ryoichi Saito iD und 1 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Toru Sakatani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyoto University School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Circulating tumor DNA (ctDNA) analysis is an alternative to tissue biopsy for genotyping in various cancers. We aimed to establish a plasma ctDNA sequencing assay, then evaluate its clinical utility in advanced urothelial cancer (UC). MATERIALS AND METHODS This study included 82 patients with muscle-invasive or metastatic UC. A total of 158 blood samples and 73 tumor tissue samples were sequenced using our designed panel covering 53 UC-relevant genes and TERT promoter. We investigated the association between the proportion of ctDNA in total cell-free DNA (ctDNA fraction) and response to pembrolizumab treatment. ctDNA dynamics were explored during systemic therapy. RESULTS In paired tissue-ctDNA samples with estimated tumor fraction, half (50.2%) of the somatic mutations were shared between both sources, while some (17.6%) mutations were found only in ctDNA. In the metastatic setting, on-treatment increase in ctDNA fraction during pembrolizumab treatment was significantly associated with a poor response rate (18.7% v 76.1%; P = .001) and progression-free survival (median 2.8 v 9.8 months; P < .001). A comparison of cancer cell fraction, the fraction of tumor cells carrying somatic mutations, between pembrolizumab initiation and on-treatment showed a strong correlation among patients where ctDNA fraction increased during treatment ( r = 0.73). By contrast, no correlation was observed in patients without ctDNA fraction increase ( r = 0.09). Most mutations newly detected at pembrolizumab resistance have already been identified in tumor tissues at earlier stages. CONCLUSION Our newly established assay is suitable for assessing the genomic profile of ctDNA in patients with advanced UC. Our data may support future analyses of prognostic or predictive biomarkers for UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNABiomarkers, TumorHumansMaleFemaleAgedMiddle AgedAged, 80 and overAntibodies, Monoclonal, HumanizedUrologic NeoplasmsAdultUrinary Bladder NeoplasmsCarcinoma, Transitional CellMutation

Substanzen

Circulating Tumor DNABiomarkers, TumorpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Kyoto University School of Medicine, Kyoto, Japan.
  • Department of Urology, Kansai Medical University, Hirakata, Japan.
  • Department of Urology, University of Miyazaki, Miyazaki, Japan.
  • Department of Urology, Nagoya University School of Medicine, Aichi, Japan.

ORCID-Profile: Toru Sakatani, Takayuki Sumiyoshi, Kenji Nakamura, Takeshi Sano, Atsuro Sawada, Shusuke Akamatsu, Ryoichi Saito, Takashi Kobayashi

Zitieren

APA

Sakatani, T., Sumiyoshi, T., Kita, Y., Takada, H., Nakamura, K., Hamada, A., Murakami, K., Sano, T., Goto, T., Sawada, A., Akamatsu, S., Saito, R., & Kobayashi, T. (2025). Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00472

Vancouver

Sakatani T, Sumiyoshi T, Kita Y, Takada H, Nakamura K, Hamada A, et al. Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-24-00472

BibTeX
@article{Sakatani2025,
  author = {Sakatani, Toru and Sumiyoshi, Takayuki and Kita, Yuki and Takada, Hideaki and Nakamura, Kenji and Hamada, Akihiro and Murakami, Kaoru and Sano, Takeshi and Goto, Takayuki and Sawada, Atsuro and Akamatsu, Shusuke and Saito, Ryoichi and Kobayashi, Takashi},
  title = {Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00472}
}
Kostenlos starten →